PremiumThe FlyAbbVie downgraded to Neutral from Buy at Citi AbbVie Hold Rating: Balancing Growth in Immunology and Neuroscience Amidst Humira Challenges and Macroeconomic Uncertainties AbbVie Expands Board, Appoints New Independent Director PremiumThe FlyAbbVie price target raised to $204 from $200 at BofA AbbVie price target lowered to $205 from $230 at HSBC AbbVie: Strong Financial Performance and Growth Prospects Drive Positive Analyst Outlook PremiumThe FlyAbbVie sees Q2 adjusted EPS $3.26-$3.30, consensus $3.05 AbbVie sees FY25 adjusted gross margin 84% of sales AbbVie says ‘significant progress’ continues with the pipeline 
